// Biotech and Pharma Therapeutics
The Year the Orthopedic Market Reinvented Itself
December 17, 2025 / Orthopedic Market / Spinal Implants / Johnson & Johnson / Stryker Strategy / Interventional Spine
In 2025, the orthopedic market underwent major restructuring as Johnson & Johnson spun off DePuy Synthes and Stryker exited spinal implants to focus on interventional spine. Innovation, specialization, and strategic refocusing are redefining orthopedic care and medtech investment.
6 Biotechs That Could Be Big Pharma’s Next M&A Target
December 17, 2025 / Biotech M&A Targets / GLP-1 Obesity Drugs / Inflammation Therapeutics / Neuropsychiatry Pipeline / Pharma Acquisitions
Biotechs like Abivax, Maplight, and Structure Therapeutics are emerging as top M&A targets, driven by promising assets in inflammation, neuropsychiatry, and obesity. Recent clinical successes and strategic positioning make them attractive prospects for Big Pharma’s next acquisition wave.
How the FDA could soon upend vaccine trials
December 17, 2025 / FDA Vaccine Trials / Immunobridging Policy / Vaccine Safety Debate / Clinical Endpoints / Regulatory Reform
The FDA may overhaul vaccine trial standards by requiring clinical efficacy endpoints over immunobridging, sparking backlash from experts warning it could delay access to critical vaccines. Critics argue the proposal lacks evidence and bypasses formal regulatory processes.
40% of Nurses Planning to Quit: How Streamlined EHR Workflows Can Save the Profession
December 17, 2025 / Nurse Burnout / EHR Workflow Optimization / Documentation Burden / AI in Healthcare / Nursing Shortage Solutions
A KLAS report finds 40% of nurses plan to leave the profession by 2029, with documentation burden as a leading cause. Streamlined EHR workflows, AI tools, and reduced redundancy significantly improve nurse satisfaction and may help reverse burnout trends.
CDC’s controversial new hep B vaccine guidance: everything you need to know
December 17, 2025 / CDC Hepatitis B / Newborn Vaccine Policy / ACIP Recommendation / Vaccine Controversy / Public Health Guidance
The CDC has reversed longstanding guidance recommending hepatitis B vaccination at birth, following an ACIP vote. The decision has sparked controversy among experts concerned about public health impacts and the irregular process by which the policy change was adopted.
// 4th Industrial Revolution
When Inaction Becomes Negligence in the Age of AI
December 17, 2025 / AI Medical Negligence / Diagnostic Omission Risk / Lung Cancer AI / Standard of Care / Healthcare AI Integration
As AI becomes integral to clinical practice, failing to adopt proven diagnostic tools may soon constitute medical negligence. The evolving standard of care now includes leveraging AI to avoid diagnostic omissions, especially in high-impact conditions like lung cancer.
Hundred Health Launches Integrated Platform to Unify Lab Data, Wearables, and Medical History
December 17, 2025 / Personalized Health Platform / Wearable Health Data / Lab Integration App / Preventive Health Management / Digital Health Optimization
Hundred Health’s new platform integrates EMRs, lab tests, wearables, and lifestyle data into personalized, evidence-based 100-day health plans. It aims to close the gap between health data and actionable care, improving engagement, outcomes, and long-term wellness.
Key Data Management Efforts to Ensure Your Organization is Ready for AI Solutions
December 17, 2025 / AI Data Governance / Healthcare Interoperability / Clinical Data Quality / Medical AI Readiness / Health IT Strategy
Healthcare organizations must prioritize robust data governance, standardization, and interoperability to prepare for AI integration. High-quality, secure, and clinically contextualized data is essential to ensure ethical, effective, and regulatory-compliant AI deployment in patient care and operational workflows.
Mass General Brigham announces AI company and clinical trial screening tool
December 16, 2025 / AI Clinical Trials / Patient Screening Tool / Healthcare AI Innovation / EHR Data Analytics / Trial Eligibility Automation
Mass General Brigham launched AIwithCare and its RECTIFIER tool to automate clinical trial screening using generative AI. RECTIFIER enhances trial matching accuracy, reduces manual review, and supports faster enrollment across specialties like oncology, cardiology, and neurology.
Why IHI 2025 Felt More Human Than High-Tech
December 17, 2025 / Patient Safety / Healthcare Equity / Clinician Burnout / Quality Improvement / Human-Centered Care
IHI 2025 emphasized human-centered healthcare improvement—focusing on patient safety, clinician well-being, equity, and outcomes—over tech-centric solutions. AI was present but secondary, with collaborative, iterative progress and leadership culture highlighted as central to sustainable healthcare transformation.
// Business & Markets
RA Capital backs drug for rare kind of chronic pain
Ambros Therapeutics raised $125M to advance neridronate, a bisphosphonate approved in Italy, toward U.S. approval for complex regional pain syndrome type I. Backed by RA Capital, the drug may offer a non-opioid option for chronic pain management.
Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road
December 17, 2025 / Mythic Therapeutics Shutdown / NSCLC Clinical Trial / Antibody Drug Conjugate / Oncology Biotech Closure / MYTX-011 FateControl
Mythic Therapeutics is shutting down after ending its Phase 1 NSCLC trial of MYTX-011 due to failed fundraising. Despite promising safety and efficacy, all assets, including the FateControl ADC platform, are now up for sale.
Addition emerges with $100M to make gene therapies for chronic and rare diseases
December 17, 2025 / Gene Therapy Innovation / Lipid Nanoparticles RNA / Rare Disease Treatment / Genome Targeting Technology / Addition Therapeutics Launch
Addition Therapeutics launched with $100M to develop gene therapies using lipid nanoparticles and RNA-guided enzymes to insert DNA into specific genome sites—offering a potentially safer, more durable, and cost-effective alternative to traditional viral-based gene therapies.
Harbour BioMed and BMS sign multi-specific antibody collab
December 17, 2025 / Multi-Specific Antibodies / Oncology Immunology Therapies / Harbour BioMed BMS / Antibody Discovery Partnership / Biotech Collaboration Deal
Harbour BioMed and Bristol Myers Squibb have entered a global partnership to co-develop multi-specific antibodies for oncology and immunology, with Harbour eligible for up to $1.125 billion in payments plus royalties based on development and commercial success.
T-CURX announces $20M Series A first closing
December 17, 2025 / CAR-T Therapy / Non-Viral Gene Delivery / T-CURX Funding / In Vivo Immunotherapy / AML Solid Tumors
T-CURX secured $20M in Series A funding to advance its non-viral CAR-T therapies for AML, CLL, and solid tumors, and to develop scalable in vivo CAR-T technologies using lipid nanoparticles for broader, cost-effective global access.
// Legal & Regulatory
Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection
December 17, 2025 / Peanut Allergy Patch / Viaskin Phase 3 Trial / DBV Technologies FDA / Pediatric Allergy Treatment / Immunotherapy Skin Patch
DBV Technologies’ Viaskin peanut allergy patch succeeded in a Phase 3 trial, reviving its FDA prospects after a 2020 rejection. The company will reapply in 2026 to treat peanut allergies in children aged 4 to 7.
Norgine gets in on Vir’s hepatitis D program with €550 European licensing pact
December 17, 2025 / Hepatitis D Treatment / Vir Biotechnology Deal / Norgine Licensing Agreement / Tobevibart Elebsiran Combo / Eclipse Clinical Trial
Vir Biotechnology licensed European rights to its hepatitis D combo therapy—tobevibart and elebsiran—to Norgine in a €550M deal. Vir retains U.S. rights and shares development costs for the ongoing Eclipse clinical trial program.
FDA adds brain tumor warning to Depo-Provera label
December 17, 2025 / Depo-Provera Warning / Meningioma Brain Tumor / FDA Label Update / Pfizer Birth Control / Progesterone Risk
The FDA added a warning to Depo-Provera labels about a potential link to meningioma, a brain tumor. This follows international actions and lawsuits alleging Pfizer failed to disclose risks associated with long-term progesterone-based contraceptive use.
Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
December 16, 2025 / Dry Eye Treatment / FDA Approval Delay / Aldeyra Reproxalap Update / Ophthalmology Clinical Trials / PDUFA Date Shift
The FDA delayed Aldeyra’s reproxalap approval decision for dry eye disease, requesting data from a previously excluded failed trial. Despite prior written agreement, the PDUFA date has been moved to March 2026, prolonging the candidate’s regulatory uncertainty.
argenx wins UK MHRA approval of Vyvgart
December 17, 2025 / Vyvgart Approval UK / CIDP Treatment Update / Efgartigimod Alfa MHRA / Rare Neurological Disease / argenx Immunology News
The UK MHRA approved argenx’s Vyvgart (efgartigimod alfa) for adults with active chronic inflammatory demyelinating polyneuropathy (CIDP), offering a new subcutaneous treatment option following corticosteroids or immunoglobulins, and addressing a significant unmet need in this rare disease.
// Research & Development
New study reveals how kimchi boosts the immune system
December 17, 2025 / Kimchi Immune Benefits / Fermented Foods Health / Immune System Boost / Gut Health Nutrition / Kimchi Clinical Study
A new clinical study using single-cell genetic analysis shows that regular kimchi consumption enhances immune function by boosting key immune cell activity and preventing overreactions, with benefits influenced by fermentation methods.
Keytruda, Padcev keep winning streak with another patient survival benefit in bladder cancer
December 17, 2025 / Keytruda Padcev Bladder / MIBC Survival Benefit / Perioperative Cancer Treatment / Keynote B15 Results / Bladder Cancer Immunotherapy
Keytruda and Padcev significantly improved survival and event-free outcomes in cisplatin-eligible muscle-invasive bladder cancer patients, according to phase 3 results from the Keynote-B15 trial. The perioperative combination showed statistically and clinically meaningful benefits over standard chemotherapy.
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses
December 16, 2025 / mRNA Vaccine Immunity / Tfh Cell Activation / Germinal Center Response / Lipid Nanoparticle Adjuvant / Rational Vaccine Design
This study reveals that both mRNA and lipid nanoparticles in mRNA vaccines synergistically drive T follicular helper cell differentiation by distinct mechanisms, enhancing germinal center responses, plasma cell generation, and memory B cell formation—key for effective, long-lasting immunity.
New ultrasound method accurately distinguishes fluid from solid breast masses
December 17, 2025 / Breast Cancer Ultrasound / Dense Breast Tissue / Coherence Imaging Technology / Noninvasive Diagnosis / Ultrasound Accuracy Enhancement
A new coherence-based ultrasound method from Johns Hopkins distinguishes fluid from solid breast masses with 96% accuracy, significantly outperforming traditional ultrasound and reducing unnecessary biopsies, especially for patients with dense breast tissue. Published findings suggest broad diagnostic and home-use potential.
Oncolytics eyes controlled study for pelareorep in colorectal cancer
December 17, 2025 / Pelareorep Colorectal Cancer / KRAS Mutation Therapy / Oncolytic Virus Treatment / MSS Colorectal Immunotherapy / Avastin FOLFIRI Combination
Oncolytics Biotech’s pelareorep, combined with Avastin and FOLFIRI, showed a 33% response rate and improved survival in KRAS-mutant, microsatellite-stable metastatic colorectal cancer—significantly outperforming historical benchmarks and supported by enhanced KRAS-specific T-cell activity in translational analyses.
// Politics
US–UK pharma deal sacrifices patients for profit
December 16, 2025 / NHS Drug Pricing / US UK Pharma Deal / Healthcare Access Equity / Pharmaceutical Profits Policy / NICE Cost Effectiveness
A new US–UK pharmaceutical agreement will raise NHS drug spending by increasing price caps and cost-effectiveness thresholds, potentially diverting funds from critical services to pharma profits—raising concerns about patient access, healthcare equity, and system sustainability.
The pharmaceutical industry’s frequent flyers and empty promises
December 13, 2025 / Drug Pricing Crisis / Pharma Profits Ethics / Prescription Access Inequality / Direct To Consumer Ads / U.S. Healthcare Affordability
While Americans face soaring drug prices and delayed care, major pharmaceutical companies report massive profits, fueled by direct-to-consumer advertising and political lobbying—raising ethical concerns about access, affordability, and corporate priorities in the U.S. healthcare system.
EMA welcomes political agreement on new EU pharmaceutical legislation
December 11, 2025 / EU Pharma Reform / EMA Legislation Update / Drug Shortage Prevention / Antimicrobial Resistance Policy / Medicine Access Europe
The EMA welcomes a major EU pharmaceutical legislation reform, streamlining regulation, boosting innovation, improving drug shortage prevention, enhancing pediatric research, and strengthening environmental safeguards, including antimicrobial resistance measures. The changes aim to modernize and simplify medicine access across the EU.
US reforms to reshape global pharmaceutical strategy
December 17, 2025 / Drug Pricing Reform / GLP-1 Access / US Pharma Policy / Obesity Drug Coverage / Domestic Drug Manufacturing
New U.S. drug pricing reforms link lower costs for GLP-1 diabetes and obesity drugs to expanded domestic manufacturing, improving access and enabling Medicare/Medicaid coverage, signaling a strategic shift in global pharmaceutical pricing and industrial policy.
Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay
December 17, 2025 / NIH Lawsuit / Whistleblower Protection / Public Health Retaliation / Jeanne Marrazzo Fired / NIAID Leadership
Former NIAID Director Jeanne Marrazzo, M.D., is suing Trump health officials, alleging her firing violated federal whistleblower protections and constitutional rights after she raised public health concerns. She seeks reinstatement, backpay, and acknowledgment of retaliatory misconduct.